-
Drug shortages are growing in the United States, and experts see no clear path to resolving them. For patients, that could mean more treatment delays, medication switches and other hassles filling a prescription.
-
There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.
-
Journalist Virginia Sole-Smith says efforts to fight childhood obesity have caused kids to absorb an onslaught of body-shaming messages. Her new book is Fat Talk.
-
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
-
The Novo Nordisk diabetes medication was found to cause significant weight loss in users and has since become a blockbuster drug and very big business.
-
WeightWatchers' acquisition of a telehealth company is just the latest commercial push into the market for a new generation of medications that promise significant weight loss.
-
The company is tapping into a red-hot market for drugs that address obesity with the purchase of telehealth operator Sequence, which can prescribe medications such as Ozempic, Wegovy and Trulicity.
-
The platform banned food advertising, yet many videos viewed by millions of kids continue to showcase candy, soda and packaged snacks, likely affecting kids' food preferences, researchers say.
-
The national study found a small but significant decline in the average BMI of more than 14,000 schoolkids after implementation of a 2010 federal law that boosted nutrition standards for school meals.
-
Many eating disorder specialists oppose the new guidance's focus on weight loss and BMI, and say it minimizes the risk of disordered eating and will perpetuate deep-rooted, damaging stigmas.